Ameriprise
CGON icon

Ameriprise’s CG Oncology CGON Stock Holding History

Ameriprise’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9M Sell
209,477
-102,046
-33% -$6.67M ﹤0.01% 1745
2026
Q1 		$21.1M Buy
311,523
+71,046
+30% +$4.03M ﹤0.01% 1369
2025
Q4 		$9.98M Buy
240,477
+132,556
+123% +$5.49M ﹤0.01% 1911
2025
Q3 		$4.35M Sell
107,921
-2,535
-2% -$73.7K ﹤0.01% 2541
2025
Q2 		$2.87M Buy
110,456
+91,211
+474% +$2.2M ﹤0.01% 2750
2025
Q1 		$471K Sell
19,245
-2,701
-12% -$76K ﹤0.01% 3511
2024
Q4 		$629K Buy
21,946
+9,051
+70% +$310K ﹤0.01% 3433
2024
Q3 		$487K Buy
12,895
+2,419
+23% +$84.8K ﹤0.01% 3486
2024
Q2 		$331K Buy
+10,476
New +$363K ﹤0.01% 3563

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise's CGON Position: Q2 2026 in Review

Ameriprise reduced its CG Oncology (CGON) stake by 33% in Q2 2026, selling an estimated $6.67M and leaving 209,477 shares worth $14.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1745.

Ameriprise first reported a position in CGON in Q2 2024 and has held it in 9 quarters since. The position peaked at $21.1M in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Ameriprise held 209,477 shares of CG Oncology worth $14.9M as of Q2 2026.
  • Ameriprise sold 102,046 CG Oncology shares in Q2 2026, an estimated $6.67M.
  • CG Oncology made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1745 holding.
  • Ameriprise first reported a position in CG Oncology in Q2 2024 and has held it in 9 quarters since.
  • Ameriprise's CG Oncology position peaked at $21.1M in Q1 2026.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.